Skip to content
You are now leaving https://www.ionispharma.com to visit

Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

Multiple presentations on the long-term efficacy and safety of TEGSEDI ® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis   Topline data results to be presented from the Phase 1 study of AKCEA-TTR-L Rx for the treatment of Transthyretin Amyloidosis (TTR) BOSTON and CARLSBAD,